Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
scPharmaceuticals ( (SCPH) ) just unveiled an announcement.
On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement with West Pharmaceutical Services, Inc. for the SmartDose® drug delivery system, extending the agreement’s term until December 31, 2027. The amendment outlines the company’s financial responsibilities upon termination, impacting its operational commitments and strategic partnerships in the drug delivery market.
The most recent analyst rating on (SCPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.
Spark’s Take on SCPH Stock
According to Spark, TipRanks’ AI Analyst, SCPH is a Neutral.
scPharmaceuticals’ overall stock score is primarily influenced by its financial instability, marked by high debt levels and negative cash flows. Despite strong revenue growth and strategic advancements highlighted in the earnings call, the company’s valuation challenges and mixed technical indicators contribute to a lower score. The focus on improving financial health and operational efficiency remains crucial for future stability.
To see Spark’s full report on SCPH stock, click here.
More about scPharmaceuticals
scPharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery systems.
Average Trading Volume: 318,245
Technical Sentiment Signal: Buy
Current Market Cap: $258.5M
Learn more about SCPH stock on TipRanks’ Stock Analysis page.